Angiotensin II receptor blockers improve peripheral endothelial function: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Li, Shuang ^a   Wu, Yan ^a   Yu, Ge ^a   Xia, Qing ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NEBIVOLOL; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; FLOW MEDIATED VASODILATATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION; VERY ELDERLY; DRUG EFFECTS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR ENDOTHELIUM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84896925546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090217     Document Type: Article

References (44)

1. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-32. (Pubitemid 38786440)
2. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160. (Pubitemid 37188333)
3. Inaba Y, Chen JA, Bergmann SR (2010) Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 26: 631-640.
4. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, et al. (2000) Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101: 1130-1137. (Pubitemid 30146614)
5. Watanabe T, Barker TA, Berk BC (2005) Angiotensin II and the endothelium - Diverse signals and effects. Hypertension 45: 163-169. (Pubitemid 40179951)
6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal 34: 2159-+.
7. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al. (2013) 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA.
8. Shahin Y, Khan JA, Samuel N, Chetter I (2011) Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 216: 7-16.
9. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, et al. (2004) Comparison of effects of Losartan, Irbesartan, and Candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. American Journal of Cardiology 93: 1432-1435. (Pubitemid 38692481)
10. Sola S, Mir MQS, Cheema FA, Khan-Merchant N, Menon RG, et al. (2005) Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome - Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 111: 343-348. (Pubitemid 40165342)
11. Rajagopalan S, Kariisa M, Dellegrottaglie S, Bard RL, Kehrer C, et al. (2006) Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 8: 783-790.
12. Warnholtz A, Ostad MA, Heitzer T, Thuneke F, Frohlich M, et al. (2007) AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Atherosclerosis 194: 439-445. (Pubitemid 47513075)
13. Perrone-Filardi P, Corrado L, Brevetti G, Silvestro A, Dellegrottaglie S, et al. (2009) Effects of AT1 Receptor Antagonism With Candesartan on Endothelial Function in Patients With Hypertension and Coronary Artery Disease. Journal of Clinical Hypertension 11: 260-265.
14. Pelliccia F, Pasceri V, Cianfrocca C, Vitale C, Speciale G, et al. (2010) Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: A randomized, double-blind, placebo-controlled study. Atherosclerosis 210: 510-515.
15. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, et al. (2010) Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 140: 73-81.
16. Lunder M, Janic M, Sabovic M (2012) Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Prev Cardiol 19: 1243-1249.
17. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, et al. (2003) Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41: 1281-1286. (Pubitemid 36706078)
18. Trevelyan J, Needham EWA, Morris A, Mattu RK (2005) Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. Heart 91: 1053-1057. (Pubitemid 41060015)
19. Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, Arantes Nogueira E, Yugar-Toledo JC, et al. (2006) Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade. J Clin Hypertens (Greenwich) 8: 803-809; quiz 810-801.
20. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, et al. (2001) Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103: 799-805. (Pubitemid 32163876)
21. Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, et al. (2003) Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 4: 197-203. (Pubitemid 37407169)
22. Koh KK, Quon MJ, Lee Y, Han SH, Ahn JY, et al. (2007) Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 28: 1440-1447. (Pubitemid 47343820)
23. Sozen AB, Kayacan MS, Tansel T, Celebi A, Kudat H, et al. (2009) Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. J Int Med Res 37: 996-1002.
24. Morimoto S, Yano Y, Maki K, Sawada K (2006) Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 29: 567-572. (Pubitemid 44437358)
25. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, et al. (2007) Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 50: 367-371.
26. Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, et al. (2010) Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5: 1174-1181.
27. Wei D, He WY, Lv QZ (2012) Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. CNS Neurosci Ther 18: 400-405.
28. Takiguchi S, Ayaori M, Uto-Kondo H, Iizuka M, Sasaki M, et al. (2011) Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res 34: 686-692.
29. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, et al. (2007) Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 25: 785-791. (Pubitemid 46398873)
30. Chung NA, Beevers DG, Lip G (2004) Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 13: 183-189. (Pubitemid 38967763)
31. Bell L, Madri JA (1990) Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 137: 7-12. (Pubitemid 20229584)
32. Barrow SE, Dollery CT, Heavey DJ, Hickling NE, Ritter JM, et al. (1986) Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol 87: 243-247. (Pubitemid 16165908)
33. O'Kane KP, Webb DJ, Collier JG, Vallance PJ (1994) Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 38: 311-315.
34. Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM (1992) Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 71: 137-144.
35. Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G (1999) Interactions among ACE, kinins and NO. Cardiovasc Res 43: 549-561. (Pubitemid 29369254)
36. Alreja G, Joseph J (2011) Renin and cardiovascular disease: Worn-out path, or new direction. World J Cardiol 3: 72-83.
37. Pellacani A, Brunner HR, Nussberger J (1994) Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 87: 567-574. (Pubitemid 24353472)
38. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H (1982) Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4: 966-972. (Pubitemid 13204034)
39. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66: 883-890. (Pubitemid 20126420)
40. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265: 22348-22357. (Pubitemid 120014308)
41. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, et al. (1995) Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75: 71B-74B.
42. Panza JA, Quyyumi AA, Callahan TS, Epstein SE (1993) Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 21: 1145-1151. (Pubitemid 23106189)
43. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68: 1190-1198. (Pubitemid 43246436)
44. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16: 3038-3045. (Pubitemid 44743501)